Charles River Laboratories International, Inc.
CRL · NYSE
12/31/2024 | 12/28/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $9,485 | – | $12,110 | $11,072 |
| - Cash | $195 | $195 | $277 | $234 |
| + Debt | $2,724 | $2,724 | $3,066 | $3,097 |
| Enterprise Value | $12,014 | – | $14,900 | $13,935 |
| Revenue | – | $4,050 | $4,129 | $3,976 |
| % Growth | – | -1.9% | 3.9% | – |
| Gross Profit | – | $1,332 | $1,503 | $1,463 |
| % Margin | – | 32.9% | 36.4% | 36.8% |
| EBITDA | – | $581 | $1,032 | $986 |
| % Margin | – | 14.3% | 25% | 24.8% |
| Net Income | – | $10 | $475 | $486 |
| % Margin | – | 0.3% | 11.5% | 12.2% |
| EPS Diluted | – | 0.2 | 9.22 | 9.48 |
| % Growth | – | -97.8% | -2.7% | – |
| Operating Cash Flow | – | $735 | $684 | $620 |
| Capital Expenditures | – | -$233 | -$319 | -$325 |
| Free Cash Flow | – | $502 | $365 | $295 |